What patents control Darzalex (daratumumab) biosimilar manufacturing?
Darzalex is a monoclonal antibody treatment, so biosimilar manufacturers focus on two different patent “buckets” when planning commercial production: patents on the underlying drug substance/product (including the antibody and its formulation) and patents tied to manufacturing methods (processes used to make the antibody). [1]
In practice, this means biosimilar firms must evaluate whether their manufacturing process could infringe a method patent, even if the end product is intended to be biosimilar. Method and process patents often cover specific steps such as upstream cell culture, purification, viral clearance, formulation, or other defined parameters used to make the antibody. [1]
Are biosimilar manufacturers allowed to use Darzalex manufacturing methods if they avoid product patent claims?
Avoiding product-related claims does not automatically solve method/process exposure. A company can still face infringement risk if it uses a manufacturing approach that falls within the scope of a protected method claim. That is why biosimilar launch planning typically includes both a product comparability strategy and a manufacturing-process freedom-to-operate (FTO) review focused on method patents. [1]
What does “manufacturing patent risk” usually mean for daratumumab biosimilars?
When people search “biosimilar patents manufacturing,” they are usually looking for the practical impact of patents on production timelines. Patent protection can delay biosimilar launch if regulators approve the biosimilar but litigation prevents commercialization, or if the biosimilar maker needs to change its process design to reduce infringement risk.
For antibody biosimilars, process design matters because minor differences in purification steps, chromatography conditions, viral inactivation/clearance strategy, or formulation handling can affect whether the process fits a patent claim. That makes manufacturing an area where patent-scope analysis is often essential. [1]
Where can I find patent and litigation details for Darzalex biosimilar manufacturing?
DrugPatentWatch.com tracks patent and related information for branded drugs and can be a starting point for researching which patents are associated with daratumumab (Darzalex) and how they may affect biosimilar entry. [1]
If you want, tell me which biosimilar (brand/name of the applicant) you mean, and I can help narrow to the most relevant patent-manufacturing issues for that specific product.
Sources
[1] https://www.drugpatentwatch.com/